3-Hydroxyphenazepam is a benzodiazepine renowned for its hypnotic, sedative, anxiolytic, and anticonvulsant attributes. Notably, it serves as an active metabolite of phenazepam and also acts as the active metabolite of the benzodiazepine prodrug cinazepam. In comparison to phenazepam, 3-hydroxyphenazepam exhibits reduced myorelaxant effects but remains largely on par in most other aspects. Much like its benzodiazepine counterparts, 3-Hydroxyphenazepam functions as a positive allosteric modulator of the GABAA receptor’s benzodiazepine site, boasting an EC50 value of 10.3 nM. It has garnered attention for being made available online as a designer drug, contributing to its growing reputation.
What is 3-Hydroxyphenazepam? 3-Hydroxyphenazepam is a benzodiazepine with hypnotic, sedative, anxiolytic, and anticonvulsant properties. It is both an active metabolite of phenazepam and a metabolite of the benzodiazepine prodrug cinazepam.
How does 3-Hydroxyphenazepam compare to Phenazepam? When compared to phenazepam, 3-Hydroxyphenazepam has diminished myorelaxant properties but is approximately equivalent in most other aspects.
What is the Mechanism of Action for 3-Hydroxyphenazepam? Like other benzodiazepines, 3-Hydroxyphenazepam behaves as a positive allosteric modulator of the benzodiazepine site of the GABAA receptor.
Has 3-Hydroxyphenazepam been sold as a designer drug? Yes, 3-Hydroxyphenazepam has been sold online as a designer drug.
Are there any potential side effects associated with 3-Hydroxyphenazepam? Common side effects of benzodiazepines like 3-Hydroxyphenazepam can include drowsiness, dizziness, and impaired coordination. It’s essential to use such substances responsibly and under the guidance of a healthcare professional.
Is 3-Hydroxyphenazepam regulated or controlled? Regulatory measures may vary by country or region. It’s crucial to check your local regulations and laws regarding the sale and use of 3-Hydroxyphenazepam.
Are there any studies or resources for further information? Yes, there are scientific studies available that provide more in-depth information about 3-Hydroxyphenazepam. You can refer to the citations provided in the previous message for additional reading.
References
Valdman AV, ed. (31 May 1986). “Drug dependence and emotional behavior: neurophysiological and neurochemical approaches. Consultants Bureau. ISBN 978-0-306-10984-3.
Komsta L, Waksmundzka-Hajnos M, Sherma J, eds. (20 December 2013). “Thin Layer Chromatography in Drug Analysis.” CRC Press. pp. 299–. ISBN 978-1-4665-0715-9.
Schukin SI, Zinkovsky VG, Zhuk OV (2011). “Elimination kinetics of the novel prodrug cinazepam possessing psychotropic activity in mice.” Pharmacological Reports. 63 (5): 1093–1100. doi:10.1016/s1734-1140(11)70628-4.
“Phenazepam Pre-Review Report” (PDF). World Health Organization (WHO). November 2015.
Kopanitsa MV, Zbarska SM, Boychuk YA, Krishtal OA (2000). “Modulation of GABA-activated currents by phenazepam and its metabolites in isolated rat purkinje neurons.” Neurophysiology. 32 (3): 192. doi:10.1007/BF02506568.
Golovenko NY, Larionov VB (2014). “Pharmacodynamical and Neuroreceptor Analysis of the Permeability of the Blood-Brain Barrier for Derivatives of 1,4-Benzodiazepine.” Neurophysiology. 46 (3): 199–205. doi:10.1007/s11062-014-9429-2.
“3-hydroxyphenazepam”. New Synthetic Drugs Database. Archived from the original on 2016-09-28. Retrieved 2016-05-30.
Pettersson Bergstrand M, Helander A, Hansson T, Beck O (April 2017). “Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays.” Drug Testing and Analysis. 9 (4): 640–645.
Moosmann B, Bisel P, Franz F, Huppertz LM, Auwärter V (November 2016). “Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines – an update comprising adinazolam, cloniprazepam, fonazepam, 3-hydroxyphenazepam, metizolam and nitrazolam.” Journal of Mass Spectrometry. 51 (11): 1080–1089.
Manchester KR, Maskell PD, Waters L (March 2018). “Experimental versus theoretical log D7.4 , pKa and plasma protein binding values for benzodiazepines appearing as new psychoactive substances.” Drug Testing and Analysis. 10 (8): 1258–1269.
